What Intrarosa Vaginal Inserts Treats: Main Uses and Benefits

This prescription medication is generally applied in the symptomatic management of vulvar and vaginal atrophy (VVA), a condition linked to the decline in estrogen levels. The use is considered relevant for managing the symptom of dyspareunia, or painful intercourse. Intrarosa is commonly used across conditions presenting with moderate to severe symptoms of atrophy, helping address symptom clusters such as dyspareunia, vaginal dryness, and local irritation.

---

Easing Painful Intercourse (Dyspareunia)

Intrarosa is generally applied in situations involving symptoms related to physical discomfort during or after sexual activity. This focus on dyspareunia may be part of symptomatic management that helps ease the overall symptom load of atrophy. By addressing this distressing manifestation, the treatment is relevant for managing symptoms that interfere with daily functioning and supports general well-being during symptomatic phases.

Managing Moderate to Severe Vaginal Atrophy Symptoms

The medication may be applied in addressing symptom clusters that become intense or disruptive, such as vaginal dryness and local irritation resulting from chronic VVA. It provides supportive therapeutic benefit that is commonly used to help with symptoms that create noticeable physiological strain. It contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Dyspareunia Intrarosa is relevant for managing a primary, highly disruptive symptom of VVA: pain during sexual intercourse.

Eligibility for Intrarosa Vaginal Inserts

Intrarosa (prasterone) vaginal inserts are officially indicated only for use in postmenopausal women.

Populations That Must Not Use Intrarosa (Contraindications)

Use of Intrarosa is strictly contraindicated in women with:

• Undiagnosed abnormal genital bleeding.
• Known hypersensitivity to prasterone or any ingredient in the formulation.

Restricted Use and Excluded Populations

The following groups should not use Intrarosa or are not indicated for its use:

• Pre-menopausal or fertile women.
• Women who are pregnant or breast-feeding (use must be discontinued immediately if pregnancy occurs).
• The pediatric population (use is not established).

Caution and close monitoring are required for women with certain conditions, including a current or past history of breast cancer, known or suspected estrogen-dependent malignant tumors, untreated endometrial hyperplasia, or acute liver disease or a history of liver disease. Treatment continuation is only recommended if the benefit outweighs the risk, which requires regular evaluation by a healthcare provider.

Officially Documented Systemic Interaction Status

The interaction profile of Intrarosa (prasterone) is primarily defined by its specific route of administration. The product is formulated as a vaginal insert for local action, which results in minimal absorption of the active ingredient into the bloodstream. Due to this minimal systemic exposure, official regulatory documents explicitly state that there are no known drug-drug interactions with other medicinal products that are administered systemically (e.g., oral medications).

This regulatory finding confirms that there are no formal warnings or restrictions in the labeling for co-administering Intrarosa with systemic drugs that typically involve metabolic pathways, such as CYP enzymes, or specific transport proteins. Consequently, no systemic drug combinations are formally classified as contraindicated or requiring dose adjustment based on interaction risk.

Local Administration Restrictions

The only procedural constraint noted in official regulatory sources relates to co-administration at the local site. To prevent interference with the intended delivery and action of the prasterone insert, official labeling advises against the concomitant use of other local vaginal products.

Food, Alcohol, and Supplements

Official prescribing information contains no specific restrictions or warnings regarding the use of Intrarosa with food, alcoholic beverages, or herbal supplements. The limited systemic impact of the prasterone insert eliminates the need for restrictions related to these substances.

Local Prohormone Activation (Intracrine Action)

The core mechanism involves the drug's active ingredient, prasterone (DHEA), acting as an inactive steroid precursor. Upon absorption into the vaginal cells, it is locally and immediately converted by steroidogenic enzymes into the active sex steroids: estrogen and androgen. The mechanism is defined as intracrine action, where hormone synthesis and activity occur primarily within the target tissue, resulting in minimal entry into the systemic circulation.

---

Receptor Activation and Tissue Maturation

These locally synthesized estrogen and androgens activate their respective nuclear receptors (ER and AR) within the epithelial and stromal cells. This receptor agonism initiates gene transcription, which drives the biological processes necessary for cell growth, differentiation, and tissue maintenance. The influence on gene expression affects the structural integrity, elasticity, and blood flow within the affected tissues, and the key resulting physiological effect is the stimulation of vaginal epithelial cell maturation and proliferation.

---

Modulation of the Vaginal Microenvironment

Restored signaling leads to an increase in the thickness and resilience (trophism) of the vaginal wall. This also promotes the production of glycogen, which is then metabolized into lactic acid. This process leads to a decrease in vaginal pH, promoting a transition toward an acidic range. These structural and biochemical changes collectively modulate the vaginal microenvironment, contributing to structural integrity and localized function.

The Intrarosa vaginal insert (prasterone 6.5 mg) is prescribed for intravaginal administration once daily at bedtime to treat moderate to severe painful intercourse, a symptom of vulvar and vaginal atrophy due to menopause.

Administration Instructions

Before handling the insert and applicator, patients should empty their bladder and wash their hands. The insert can be administered using the provided single-use disposable applicator or, in some cases, with clean fingers.

Step	Action
1. Preparation	Remove one applicator and activate it by pulling back the plunger until it stops. Open the insert packaging, taking care not to drop the insert on an unsanitary surface.
2. Loading	Place the flat end of the vaginal insert into the open end of the activated applicator.
3. Insertion	Select a comfortable position (lying down or standing). Gently slide the insert end of the applicator into the vagina as far as it can comfortably go without forcing it.
4. Release	Press the applicator plunger with your index finger to release the insert. Withdraw the applicator and discard it, as it is designed for one-time use only.

If a dose is missed, it should be administered as soon as remembered. However, if the next scheduled dose is due in less than eight hours, the missed dose should be skipped. Patients should not use two inserts at once to make up for a missed dose. The product should be stored between 41°F and 86°F (5°C and 30°C) and should not be kept in areas subject to high temperatures, such as a hot car or near a heater, as this may cause it to melt.

Research evidence / Overview of Studies for Intrarosa Vaginal Inserts

This overview summarizes the official clinical research and regulatory evidence for Intrarosa Vaginal Inserts, focusing on the types of studies conducted, what outcomes were measured, and where evidence limitations exist. This information is intended to provide context about the research base and is not medical advice.

---

Evidence for Use in Moderate to Severe Painful Intercourse (Dyspareunia)

The primary evidence for Intrarosa is based on large, controlled clinical trials that research examined in women reporting painful intercourse (dyspareunia), which is the medical term for pain experienced during sexual activity due to postmenopausal changes. To evaluate the research agent, researchers designed and conducted two main randomized, double-blind, placebo-controlled Phase 3 trials over a 12-week period. This type of study is applied in research requiring high methodological rigor, because neither the patients nor the clinicians knew whether the study participant received the active drug or an inactive insert (placebo).

In these short-term studies, researchers used four co-primary outcomes to evaluate the agent. These outcomes included the patient-reported change in the severity score of painful intercourse, as well as changes in physiological markers of vaginal health: vaginal pH (a measure of acidity) and the cellular composition of the vaginal lining. Studies reported measurements of difference, compared to placebo, across all four co-primary endpoints. However, study documentation indicates that reported outcomes for other individual symptoms of vulvar and vaginal atrophy (VVA), such as vaginal dryness or irritation, did not consistently demonstrate a pattern of difference compared to the placebo across all pivotal trials.

---

Long-Term Research and Follow-up Duration

Clinical research also explored how patterns of change might evolve over a longer timeframe. While the primary data related to short-term measures came from 12-week trials, an additional open-label, non-comparative trial was conducted to monitor outcomes over a defined time interval of up to 52 weeks (one year). This intermediate-term research explored the consistency of outcomes measured in the vaginal environment and tissue cell composition throughout the year of observation. However, the follow-up durations were limited; long-term outcomes are not well characterized, and evidence remains limited for outcomes beyond the one-year study duration.

---

Evidence Gaps and Uncertainty in the Research

While the research provides context for the primary indication, several areas remain uncertain or insufficiently studied. A key limitation is the absence of head-to-head trials; comparative evidence is lacking because the core research did not directly study the medication against other local hormone treatments for VVA. Furthermore, long-term outcomes are not well characterized. Data are still emerging, and research currently describes patterns up to one year. Overall, study results reflect the specific conditions under which they were conducted and findings describe group patterns, not personal outcomes.

Common questions about Intrarosa Vaginal Inserts (FAQ)

Q: How does Intrarosa work to relieve symptoms of painful intercourse after menopause?

Intrarosa contains prasterone, which is a naturally occurring steroid. According to official product information, prasterone is converted into active hormones (estrogens and androgens) inside the vaginal cells. These hormones are thought to help address moderate to severe symptoms of vulvar and vaginal atrophy, including painful intercourse (dyspareunia) related to menopause.

Q: Can I use Intrarosa if I am taking other hormonal products?

Regulatory documents indicate that the effect of Intrarosa on other hormone products, such as those taken by mouth, has not been studied. Therefore, regulatory sources emphasize the importance of discussing all medicines and products you use with a healthcare professional before considering Intrarosa.

Q: Does Intrarosa require a prescription?

Yes. Intrarosa Vaginal Inserts are classified as a prescription medicine. Official product information states that this product is only available with a valid prescription from a licensed healthcare provider.

Q: What is the key difference between Intrarosa and oral hormone therapy?

Intrarosa is a local vaginal treatment containing prasterone, which is inserted directly into the vagina. According to regulatory documents, the benefit is primarily local, helping to treat painful intercourse caused by vulvar and vaginal atrophy. This contrasts with oral hormone therapy, which typically provides systemic effects throughout the body.

Q: Will Intrarosa improve the physical appearance of the vulva and vagina?

Studies and official information indicate that Intrarosa is used to treat the moderate to severe symptoms of vulvar and vaginal atrophy. As the treatment targets vulvar and vaginal atrophy, it is intended to help alleviate associated physical symptoms, which may include dryness, irritation, and discomfort.

Q: What is the active ingredient in Intrarosa and what is its role?

The active ingredient in Intrarosa is prasterone, which is a steroid. According to the official product information, prasterone is known chemically as dehydroepiandrosterone (DHEA). Its role is to be converted into active hormones locally in the vaginal cells to address the symptoms of vulvar and vaginal atrophy.

Q: Is Intrarosa a type of estrogen replacement therapy?

Intrarosa is a vaginal insert containing prasterone. According to official documentation, prasterone is converted into both estrogens and androgens (male sex hormones) inside the vaginal cells. While it results in local estrogenic activity, regulatory documentation classifies it as an androgen precursor rather than a traditional estrogen replacement therapy.

Q: Can Intrarosa cause weight gain?

In clinical trials, weight increase was not listed as a common or frequently reported side effect of Intrarosa. Official safety information focuses on common local reactions reported during studies. Official documentation contains a comprehensive list of all reported side effects.

Storage and Disposal Information

Intrarosa (prasterone) vaginal inserts must be stored under specific conditions as defined by regulatory labeling to maintain product stability and integrity.

---

Storage Environment

The product must be kept at a temperature between 5 C and 30 C (41 F and 86 F). It may be stored at room temperature or in the refrigerator, but it is mandatory to keep the medicine from freezing.

Store the inserts away from heat, moisture, and direct light in a closed container. Exposure to high temperatures could cause the insert to melt.

---

Handling and Disposal

As a safety measure, Intrarosa must be kept out of the reach of children. The documented shelf life is 3 years, and outdated medicine or medicine no longer needed must not be kept.

Any unused medicinal product or waste material must be disposed of in accordance with local requirements. Patients are advised to consult a healthcare professional for specific disposal guidance.